N,N-dimethylformamidazin dihydrochloride

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N,N-dimethylformamidazin dihydrochloride
• 英文别名: N,N-dimethylformamide azine dihydrochloride；(1E,N’E)-N’-((dimethylamino)methylene)-N,N-dimethylformohydrazonamide dihydrochloride；(E)-N′-((E)-(dimethylamino)methylene)-N,N-dimethylformohydrazonamide dihydrochloride；1,2-bis[(dimethylamino)methylene]hydrazine dihydrochloride；N'-[(1E)-(dimethylamino)methylidene]-N,N-dimethylhydrazonoformamide bishydrochloride；N'-[(1E)-(dimethylamino)methylene]-N,N-dimethylhydrazonoformamide dihydrochloride；(1E,N'E)-N'-((Dimethylamino)methylene)-N,N-dimethylformohydrazonamide hydrochloride；N'-[(E)-dimethylaminomethylideneamino]-N,N-dimethylmethanimidamide;hydrochloride
• 化学式: C₆H₁₄N₄*2ClH
• 分子量: 215.126
• InChiKey: LNICZZAXNGQZHZ-PUFOULASSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  31.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N,N-dimethylformamidazin dihydrochloride 、 N,N-二苯基肼 以 吡啶 为溶剂， 反应 4.0h， 以58%的产率得到N4-(N,N-diphenylamino)-1,2,4-triazole
  参考文献：
  名称：

  Synthesis, structure and electronic properties of N-dialkylamino- and N-alkoxy-1,2,4-triazol-3-ylidene ligands

  摘要：

  4-Amino- and 4-alkoxy-1,2,4-triazoles 4a-d and 6 were readily obtained from the reaction of N,N-dimethyiformamidazin dihydrochloride 3 with hydrazines 2 and hydroxylamine 5. Alkylation of compounds 4a-d and 6 by MeOTf or MeI afforded azolium salts 9-11, which in turn were transformed into Rh(l) carbene complexes 13-15, Ag carbenes 16, and cationic Rh(l) bis-carbenes 17. Additionally.. complexes 13 and 15 were transformed into dicarbonyl derivatives 18 and 19, and the carbonyl stretching frequencies of these compounds were used to evaluate the effect of the amino and alkoxy groups in the sigma-donor ability of these 1,2,4-triazol-3-ylidenes. (c) 2005 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.jorganchem.2005.07.120
• 作为产物：
  描述：

  N,N-二甲基甲酰胺 在 氯化亚砜 、 一水合肼 作用下， 反应 19.0h， 以54%的产率得到N,N-dimethylformamidazin dihydrochloride
  参考文献：
  名称：

  1 H -1,2,3-三唑在间苯二甲酸衍生物使水凝胶形成中可控药物递送的4 H -1,2,4-三唑等位取代

  摘要：

  在这项工作中，我们表明，1,2,4-三唑基部分在5-简单的替代（4H -1,2,4-三唑-4-基）间苯二甲酸（5-TIA）由1个H ^ - 1,2,3-三唑-5-基单元可以制备水凝胶剂（click-TIA）。与5-TIA形成鲜明对比的是，它的等排异构体click-TIA在超声处理后会在水中自组装，从而形成稳定的超分子粘弹性水凝胶，临界胶凝浓度为6 g / L。由click-TIA制成的水凝胶以及由click-TIA + 5-TIA混合物制成的杂化水凝胶（摩尔比1∶0.2）用于比较材料的不同性质（即流变性质，热性质，机械稳定性，形态）。在毒性方面，与未经DMSO孵育的未经处理细胞相比，click-TIA和5-TIA均未显示对高达2.3×10 –3 g / L的HeLa细胞细胞活力的细胞毒性作用。此外，水凝胶被用于遵循一级动力学的土霉素的包封和体外控释。用于由click-TIA制成的水凝胶，在6

  DOI：

  10.1021/acs.molpharmaceut.7b01049

文献信息

• [EN] FACTOR XIa INHIBITORS<br/>[FR] INHIBITEURS DU FACTEUR XIA
  申请人：MERCK SHARP & DOHME

  公开号：WO2016015593A1

  公开（公告）日：2016-02-04

  The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

  本发明提供了一种化合物(I)及包含一种或多种所述化合物的药物组合物，以及使用所述化合物用于治疗或预防血栓、栓塞、高凝血性或纤维变化的方法。这些化合物是选择性因子XIa抑制剂或因子XIa和血浆激肽原的双重抑制剂。
• Benzimidazole and pyridylimidazole derivatives
  申请人：——

  公开号：US20030069257A1

  公开（公告）日：2003-04-10

  This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula I 1 The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABA A receptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Novel processes for preparing compounds of Formula I are disclosed. This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization of GABA A receptors in tissue sections.

  这项发明涉及苯并咪唑、吡啶咪唑和相关的双环杂环芳烃化合物，所有这些化合物都可以用公式I描述。该发明特别涉及与GABA受体的苯二氮卓位点具有高选择性和高亲和力结合的化合物。该发明还涉及包含这些化合物的药物组合物，以及将这些化合物用于治疗某些中枢神经系统（CNS）疾病。公式I化合物的新制备方法也已披露。此外，该发明还涉及将苯并咪唑、吡啶咪唑和相关的双环杂环芳烃化合物与一个或多个其他CNS药剂结合以增强其他CNS药剂效果的用途。此外，该发明还涉及将这些化合物用作GABA受体在组织切片中的定位探针的用途。
• [EN] DIAZEPANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS<br/>[FR] DIAZÉPANES, ANTAGONISTES DU RÉCEPTEUR H3 DE L'HISTAMINE
  申请人：EVOTEC NEUROSCIENCES GMBH

  公开号：WO2009095394A1

  公开（公告）日：2009-08-06

  The invention relates to compounds of formula (I) wherein R1 to R8 and X1, X2 have the meaning as cited in the description and the claims. Said compounds are useful as Histamine H3 receptor antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.

  该发明涉及式(I)的化合物，其中R1至R8和X1、X2的含义如描述和权利要求中所述。所述化合物可用作组胺H3受体拮抗剂。该发明还涉及制药组合物，制备此类化合物以及作为药物的生产和使用。
• Inhibitors of DNA Methyltransferase
  申请人：Wahhab Amal

  公开号：US20080132525A1

  公开（公告）日：2008-06-05

  The invention relates to the inhibition of DNA methyltransferase isoforms DNMT1 and DNMT3b2. The invention provides compounds and methods for inhibiting DNMT1 and DNMT3b2.

  这项发明涉及抑制DNA甲基转移酶亚型DNMT1和DNMT3b2。该发明提供了用于抑制DNMT1和DNMT3b2的化合物和方法。
• Functionalized polynucleotide compound, optionally marked and method for detecting a target nucleic acid
  申请人：DeFrancq Eric

  公开号：US06875858B1

  公开（公告）日：2005-04-05

  The invention relates to a functionalized compound of general formula (I): in which W represents a nucleotide analog, L represents a linker arm comprising at least four atoms, R 1 represents a linear or branched alkyl chain, A functionalized polynucleotide comprising at least one said compound and a labeled functionalized polynucleotide comprising at least one functionalized compound corresponding to the formula (I′). A method for detecting a target nucleic acid using a said compound is described.

  该发明涉及一种通式（I）的官能化化合物：其中W代表核苷酸类似物，L代表至少四个原子的连接臂，R1代表线性或支链烷基链，包括至少一种所述化合物的官能化多核苷酸以及包括至少一种与通式（I'）相对应的官能化化合物的标记官能化多核苷酸。描述了使用所述化合物检测目标核酸的方法。